4.07
前日終値:
$4.22
開ける:
$4.21
24時間の取引高:
551.87K
Relative Volume:
0.55
時価総額:
$259.04M
収益:
$157.08M
当期純損益:
$-70.36M
株価収益率:
-3.6614
EPS:
-1.1116
ネットキャッシュフロー:
$-71.69M
1週間 パフォーマンス:
-1.10%
1か月 パフォーマンス:
-10.13%
6か月 パフォーマンス:
+137.35%
1年 パフォーマンス:
+155.38%
Macrogenics Inc Stock (MGNX) Company Profile
名前
Macrogenics Inc
セクター
電話
301-251-5172
住所
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
MGNX
Macrogenics Inc
|
4.07 | 268.58M | 157.08M | -70.36M | -71.69M | -1.1116 |
|
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2024-11-07 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-07-31 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-05-10 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | ダウングレード | Stifel | Buy → Hold |
| 2024-05-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-04-26 | 開始されました | B. Riley Securities | Buy |
| 2024-04-09 | アップグレード | TD Cowen | Hold → Buy |
| 2024-03-04 | 繰り返されました | BTIG Research | Buy |
| 2024-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-11-22 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-11-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-02-28 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-04 | 開始されました | SMBC Nikko | Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-12 | アップグレード | Barclays | Underweight → Overweight |
| 2020-12-22 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-06-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2019-12-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-11-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Guggenheim | Neutral |
| 2019-02-07 | アップグレード | Citigroup | Sell → Buy |
| 2019-02-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-02-06 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-12-10 | ダウングレード | Raymond James | Outperform → Underperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-05-31 | 開始されました | Evercore ISI | Outperform |
| 2018-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-31 | 開始されました | Raymond James | Outperform |
すべてを表示
Macrogenics Inc (MGNX) 最新ニュース
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan
Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan
MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade
MacroGenics: Q2 Earnings Snapshot - Yahoo Finance
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - manilatimes.net
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat
Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead exercises option on MacroGenics bispecific program - Investing.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - manilatimes.net
MacroGenics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
MacroGenics (MGNX) Projected to Release Earnings on Thursday - MarketBeat
MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144 - stocktitan.net
Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX) - Stock Titan
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com
Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView
MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey
MacroGenics Inc (MGNX) Cash Flow - TradingKey
MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView
TradingKey - TradingKey
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - manilatimes.net
MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com
MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus
MacroGenics’ MGC026 meets trial threshold in head and neck cancer By Investing.com - Investing.com Nigeria
MacroGenics Advances MGC026 in Phase 1 Oncology Trial - TipRanks
MacroGenics’ MGC026 meets trial threshold in head and neck cancer - Investing.com
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
MGNX stock holds focus as MacroGenics plans and pipeline metrics matter - Ad-hoc-news.de
MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G - Stock Titan
MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends - Ad-hoc-news.de
MacroGenics Inc (NASDAQ: MGNX) Share Price, MGNX Stock News, MGNX Share Price & Updates - Kalkine
[144] MACROGENICS INC SEC Filing - Stock Titan
Form 144 MACROGENICS For: 13 July By Investing.com - Investing.com Nigeria
MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
MGNX Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline DevelopmentOperating Margin Analysis - dars.gov.et
Macrogenics Inc (MGNX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):